Novel ADC Yields Promise in FRα High, Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer, according to data presented t the 2022 SGO Annual Meeting on Women's Cancer.
Researchers announce dat from the phase III SORAYA trial, treatment with the investigational mirvetuximab, a first-in-class anti-body therapy, resulted in an objective response rate (ORR) of 32.4% (95% CI 23.6%-42.2%) in 106 patients, all of whom received prior bevacizumab.
"These results position mirvetuximab to become a practice-changing, biomarker-driven standard-of-care treatment option for patients with FRα-positive platinum-resistant ovarian cancer," reported Ursula Matulonis, MD, of the Dana-Farber Cancer Institute and Harvard Medical School.
Mirvetuximab soravtansine has been proven to demonstrate activity in some patients with FRα-high platinum-resistant and platinum-sensitive ovarian cancer. In May 2019, developer ImmunoGen suffered a setback when its first phase III trial of the agent failed to offer a boost in progression-free survival (PFS) versus chemotherapy, and the FDA recommended the developer conduct a new phase trial in patients with high FRα expression.
To conclude, the most common adverse events include ocular events, with keratopathy of all grades occurring in 36% of patients, and blurred vision.
